疫苗ETF（159643）收涨近6%，中国创新药产业已具规模

Group 1 - The core viewpoint is that the Chinese innovative pharmaceutical industry has reached a significant scale, transitioning from traditional pharmaceutical models to innovative ones, with an increasing emphasis on international markets [1] - The demand side is driven by an aging population and a rise in chronic diseases such as cardiovascular, endocrine, and orthopedic conditions, while the payment side is supported by steady growth in medical insurance revenues and the promotion of commercial insurance [1] - New technologies, particularly in AI, are accelerating industry transformation, with developments in brain-computer interfaces, early cancer screening, and AI healthcare expected to unlock new growth opportunities [1] Group 2 - The vaccine ETF (159643) has seen a nearly 6% increase, tracking the vaccine biotechnology index (980015), which includes listed companies involved in vaccine research, production, and related services [1]